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انتشار وعالقة فريوس الورم البشري احلُليمي وأنواعه مبؤشرات الورم املعروفة 
بني مرضى أورام الثدي يف الكويت
ع�سام فرن�سي�س, ب�رشى العيا�سي, �سفيقه العو�سي, كو�سم كابيال, فهد املال
امللخ�ص: الهدف: تهدف الدرا�سة اإىل توثيق العالقة بني فريو�س الورم احلليمي الب�رشي واأنواعه باأورام الثدي يف عينات من اأن�سجة الثدي 
امل�سابهة من الن�ساء الكويتيات وعالقته مبوؤ�رشات التنبوؤ بالورم املعروفة. الطريقه: متت درا�سة 144 عينه من الأن�سجة املحفوظة من 
حالت �رشطان الثدي الأقنية الغازية واأخذ البيانات املتاحة اإكلينيكيا وباثولوجيا وتت�سمن العمر, وحجم الورم, وانت�سار املر�س يف العقد 
الليمفاوية, وحالة م�ستقبالت الإ�سرتوجني و الربوج�سرتون وعامل منو الب�رشة 2. وقد مت توثيق تكرار تواجد فريو�س الورم احلليمي الب�رشي 
با�ستخدام الكيمياء اله�ستولوجية املناعية و و�سيلة التهجني اللونية.مت توثيق الأنواع الفرعية من فريو�س الورم احلليمي الب�رشي با�ستخدام 
امل�سابر لفريو�س الورم احلليمي الب�رشي CISH وقورنت نتائج CISH و IHC وارتباط فريو�س الورم احلليمي الب�رشي مع موؤ�رشات 
التنبوؤ بالورم. النتائج: كان انت�سار فريو�س الورم احلليمي الب�رشي ح�سب CISH و IHC 51 من احلالت )%35.4( و 24 )16.7%( 
حالة تواترا. كانت احل�سا�سية للك�سف عن فريو�س الورم احلليمي الب�رشي با�ستخدام CISH %37.3, واخل�سو�سية كانت %94.6. وجد 
اأن املقارنة الإح�سائية للح�سا�سية واخل�سو�سية بني CISH وIHC يف الك�سف عن فريو�س الورم احلليمي الب�رشي يعتد بها اإح�سائيا 
)P >0.001( با�ستخدام اختبار في�رش. )HPV-CISH( وجدت يف 51 من احلالت و مزيج من فريو�س الورم احلليمي الب�رشي 18 
7 من احلالت )13.7%(.  33 ,31 ,11 ,6 يف  ,16 ,11 ,6 وجدت يف حالتني )%3.9(؛ ومزيج فريو�س الورم احلليمي الب�رشي 
فريو�س الورم احلليمي الب�رشي من الثالث اأنواع 18 ,16 ,11 ,6 و كذلك/33 ,13 كانت موجودة يف حالتني )%3.9(. وكان مدى 
انت�سار HPV-CISH يف الكويتيني وغري الكويتيني )%52.9( 27 و )%37.2( 19، على التوايل. مل تالحظ اأية رابطة مع موؤ�رشات 
الورم. اخلال�صة: كان تواتر فريو�س الورم احلليمي الب�رشي يف حالت �رشطان الثدي يف الكويت CISH( 35.4%( ومن هوؤلء 52.9% 
من الكويتيني ممن وجد عندهم فريو�س الورم احلليمي الب�رشي منخف�س وعايل اخلطر.
مفتاح الكلمات: فريو�س الورم احُلليمي؛ �رشطان الثدي؛ الكيمياء اله�ستولوجية املناعية؛ التهجني املو�سعي؛الكويت.
abstract: Objectives: This study aimed to document the association of human papilloma virus (HPV) and 
its types in breast carcinoma tissues in Kuwaiti women, and correlate this with known prognostic markers. 
Methods: The clinicopathological data of archived tissue from 144 cases of invasive ductal breast carcinoma were 
studied (age, histological grade, size of tumour, lymph node metastases, oestrogen/progesterone receptors and 
human epidermal growth factor receptor 2 status). HPV frequency was documented using immunohistochemistry 
(IHC) and chromogenic in-situ hybridisation (CISH). HPV types were documented by CISH using HPV probes. 
CISH and IHC techniques were compared and HPV correlated with prognostic parameters. Results: The HPV 
prevalence as determined by CISH and IHC was 51 (35.4%) and 24 (16.7%) cases, respectively. The sensitivity of 
HPV by IHC was 37.3% and specificity was 94.6%. The sensitivity and specificity of HPV-CISH compared to HPV-
IHC was statistically significant (P <0.001). HPV-CISH was seen in 51 cases. A combination of HPV 6 and 11, and 
16 and 18 was seen in 2 (3.9%) cases, and a combination of HPV 6, 11, 31 and 33 was seen in 7 (13.7%) cases. All 
three HPV probes: 6 and 11, 16 and 18, as well as 31 and 33 were present in 2 (3.9%) cases. The prevalence of HPV-
CISH in the Kuwaiti and non-Kuwaiti populations was 27 (52.9%) and 19 (37.2%), respectively. No correlation was 
observed with the prognostic parameters. Conclusion: The frequency of HPV in breast carcinoma cases in Kuwait 
was 35.4% (CISH). Of those, 52.9% were Kuwaitis in whom both low- and high-risk HPV types were detected.  
Keywords: Human Papillomavirus; Breast Neoplasm; Immunohistochemistry; In Situ Hybridization; Kuwait.
Prevalence and Correlation of 
Human Papilloma Virus and its Types with 
Prognostic Markers in Patients with Invasive 
Ductal Carcinoma of the Breast in Kuwait
*Issam M. Francis, Bushra Al-Ayadhy, Shafiqa Al-Awadhi, Kusum Kapila, Fahd Al-Mulla
Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
*Corresponding Author e-mail: issamfrancis@gmail.com 
clinical & basic research
Issam M. Francis, Bushra Al-Ayadhy, Shafiqa Al-Awadhi, Kusum Kapila and Fahd Al-Mulla
Clinical and Basic Research | 528
Breast cancer is the most common form of cancer among women in Kuwait. In 2001, the breast cancer age-standardised 
incidence rate (ASR) was 36 among Kuwaiti and 
39.5 among non-Kuwaiti female residents.1 Since 
then, its incidence has increased rapidly. Al-
Shaibani et al. noticed that in Kuwait the majority 
of breast cancer patients were 40–49 years of age, 
and increased breast carcinoma risk was correlated 
with the menopause, recent hormone replacement 
therapy and family history.2
Well-known breast cancer risk factors associated 
with the development of breast cancer are age, 
familial history, hormonal intake, early menarche, 
late menopause, multiparity, first pregnancy at >30 
years, obesity and personal history. Nevertheless, 
in 50–80% of cases, known risk factors have not 
been identified which has generated an interest 
in identifying new factors related to this cancer.2,3 
The three most studied viruses found to cause 
breast cancer in humans are mouse mammary 
tumour virus (MMTV), the Epstein-Barr virus 
(EBV) and the human papilloma virus (HPV), 
with MMTV and EBV occurring in up to 37% and 
50% of breast carcinoma cases, respectively.4 HPV 
is accepted as carcinogenic in human cervical, 
anogenital, and head and neck cancers. Molecular 
and epidemiological studies have shown that a 
persistent infection with high-risk types of HPV 
is the most important risk factor for both cervical 
cancer and its precursors.5 Recently, the possibility 
of HPV being aetiologically-related to breast cancer 
has been debated. However, the causal role of HPV 
infection in the development of breast carcinoma 
remains controversial.6
Reports on the distribution of HPV infection in 
breast cancer are not only limited but also highly 
controversial.7 Several authors have reported the 
absence of HPV deoxyribonucleic acid (DNA) in 
breast cancer and suggested that it is improbable 
that integrated HPV is aetiologically-associated 
with the development of breast carcinoma.8–11 
However, a moderate frequency of 20–48% HPV 
infection and as high as 60–85% of HPV infection 
in breast carcinomas has been reported.7
The suspicion that HPV may also play a 
role in human breast cancer is based on the 
identification of HPV in human breast tumours 
and the immortalisation of normal human breast 
cells by HPV 16 and 18.12 Previous studies have 
demonstrated the presence of HPV types 16, 18 
and 33 in breast cancer specimens from diverse 
populations around the world: Italy, Norway, China, 
Japan, USA, Austria, Brazil, Australia, Taiwan, 
Turkey, Greece, Korea, Mexico, Hungary and 
Syria.6,13–23 The prevalence of HPV-positive breast 
cancer in these studies was reported to vary from 4% 
in Mexican to 86% in American women.13 In all the 
studies, high-risk HPV was found in tumour tissue 
only and not in the surrounding normal tissue, with 
the  exception of the study from Turkey where the 
virus was also detected in normal tissue but at a 
lower expression than in the cancerous tissue.20  
Most of the studies have used standard 
and nested polymerase chain reaction (PCR) 
techniques. The disadvantage of this technique is 
its inability to confirm whether or not a positive 
reaction is in the mammary epithelial cells.24 Very 
few studies have used in-situ molecular methods 
for the demonstration of HPV, and in three of 
them a comparison between solution PCR and 
in-situ hybridisation methods for the same set of 
specimens was made and identified oncogenic HPV 
in mammary epithelium of 12% of the collective 
total versus 22% using standard or nested PCR.18,13–
15,22,24 In-situ methods have the potential to establish 
Advances in Knowledge
- Reports on the distribution of human papilloma virus (HPV) infection in breast cancer patients are limited and highly controversial.  
- This manuscript describes the prevalence of HPV in breast carcinoma cases in Kuwait and the distribution of the low risk (HPV 6 and 
11) high risk (HPV 16 and 18) and intermediate risk (HPV 31 and 33) types in Kuwaiti and non-Kuwaiti women. Previous to this study, 
HPV and its subtypes in breast carcinoma in the Middle East had only been described in Turkey and Syria.
Applications to Patient Care
- Molecular and epidemiological studies have shown that persistent infection with high-risk HPV is an important risk factor for cervical 
cancer. The causal role of HPV in the development of breast carcinoma remains controversial. The association of HPV and breast 
carcinoma, the commonest cancer in Kuwait, has not been studied before.  
- Very few studies are available which correlate the presence of HPV with prognostic parameters in cases of breast carcinoma.  
- The frequency of HPV-positivity in breast carcinoma could help guide the HPV vaccination policy.
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more accurately the frequency of HPV in breast 
cancer tissue because of their ability to localise the 
signals in individual cells which can be categorised 
as benign or malignant.
The association of breast carcinoma with HPV 
has yet not been studied in Kuwait. The aim of this 
study was to document the association of HPV 
and its types (6, 11, 16, 18, 31 and 33) with breast 
carcinoma cases in Kuwait, both in Kuwaitis and 
non-Kuwaitis. The study also aimed to identify 
the correlation of HPV and its types with known 
prognostic and predictive markers, namely age, 
histological grade, tumour size, lymph node 
metastases, oestrogen (ER) and progesterone (PR) 
receptor expression and human epidermal growth 
factor receptor 2 (HER2/neu) amplification status. 
The secondary aim of this study was to compare 
HPV detection with immunohistochemistry (IHC) 
versus chromogenic in-situ hybridisation (CISH).
Methods
Archived formalin-fixed paraffin-embedded tissue 
from 144 cases of invasive ductal breast carcinoma, 
from the Department of Pathology at Hussain Makki 
Al-Juma Center for Specialized Surgery (HMJCSS) 
in Kuwait, were studied over a 3-year period (2009 
to 2011). The study was performed according to 
the guidelines of the local ethics committee which 
conforms to the Helsinki Declaration. Cases were 
selected in which the following clinicopathological 
data were available: age of the patient at the time 
of diagnosis, histological grade and size of tumour, 
lymph node status, ER, PR and HER2/neu status.
Histology slides were reviewed and histological 
grading of the tumour was done using the modified 
Scarff-Bloom-Richardson grading system.25 The 
size of the tumour, the number of lymph nodes 
involved, and the ER, PR and HER2/neu status were 
reviewed for uniformity.
Paraffin-embedded tissue sections of the 144 
breast cancer cases were analysed for HPV status 
by IHC and CISH. For IHC, the prefixed unstained 
tissue sections were used to demonstrate HPV by 
the standard IHC methodology using antibody 
from Dako (Carpinteria, California, USA), dilution 
of antibody (1:100) and the detection system, Dako 
EnVision, FLEX/HRP, High pH (Dako Global R 
& D, Glostrup, Denmark). Positive and negative 
controls were run with each batch. HPV staining 
was considered positive when there was distinct 
nuclear staining.
For CISH, a CISH implementation kit AP-NBT/
BCIP (Zytovision, Bremerhaven, Germany) was 
used. In CISH, all the cases were first screened for 
HPV status using the Zytovision biotin labelled 
HPV screening probe that allows the simultaneous 
screening of 7 HPV types (6, 11, 16, 18, 31, 33 and 
35) without determination of specific HPV types. 
Positive and negative controls were run with each 
batch. HPV staining was considered positive when 
there was distinct nuclear staining.
For HPV typing, all positive cases were tested 
for the specific HPV types, namely the low-risk: 6 
and 11; intermediate-risk: 31 and 33, and high-risk: 
16 and 18, types using the specific biotin labelled 
6 and 11, 31 and 33, and 16 and 18 Zytofast HPV 
DNA probes by the CISH technique.
The HPV types detected were correlated with 
the prognostic markers, namely age, histological 
grade, tumour size, lymph node metastases, ER, PR 
and HER2/neu. Data were analysed using Statistical 
Package for Social Sciences (SPSS), Version 17 
(IBM, Corp., Chicago, Illinois, USA). Univariate 
analysis was used to compare the clinical and 
pathological features with the HPV types. Fisher’s 
exact test was used to find the association between 
the two techniques of CISH and immunostaining. 
For all analyses, P <0.05 was considered statistically 
significant.    
Results
Of 144 cases of invasive ductal breast carcinoma, 
67 (46.5%) were Kuwaitis and 66 (45.9%) were non-
Kuwaitis, comprising both non-Kuwaiti Arabs and 
non-Arabs including Asians and Caucasians. In 11 
cases (7.6%), information on nationality was not 
available. The age range was 27–84 years with a 
median age of 52. There were 42 cases (29.2%) in 
the fourth and fifth decades of life. A histological 
grade of 1, 2 and 3 was documented in 5 (3.5%), 47 
(32.6%) and 86 (59.7%) of the cases, respectively. Of 
the 144 cases, tumour sizes were documented in 
139 (96.5%) cases and the size was less than 2 cm, 
2–5 cm and 5 cm or more in 19 (13.2%), 98 (68.1%) 
and 22 (15.3%) cases, respectively. Lymph nodes 
were involved in 75 (52.1%) cases but not involved 
in 56 (38.9%) cases, and data were not available in 13 
(9%) cases. For the 144 cases of breast carcinoma, 
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ER status was available for 137 (95.1%) cases; 103 
(75.2%) cases were ER-positive and 34 (24.8%) cases 
ER-negative. The PR status was available in 134 
cases, of which 88 (61.1%) cases were PR-positive 
and 46 (31.9%) cases were PR-negative. HER2/
neu, determined by IHC, was available in 135 cases 
of which 21 (15.6%) cases were positive and 114 
(84.4%) cases were negative.
HPV was detected by CISH in 51 (35.4%) 
cases and by IHC in 24 (16.7%). The correlation 
of the HPV status in breast carcinoma cases by 
CISH and IHC. A good correlation was seen in 19 
(13.2%) and 88 (61.1%) cases, being positive and 
negative, respectively, for HPV by both methods. 
The sensitivity and specificity of HPV-IHC was 
37.3% and 95.6%. The sensitivity and specificity of 
HPV-CISH was 79.2% and 73.3%. This association 
was found to be significant by Fisher’s exact test (P 
<0.001).
HPV typing performed on 51 cases found 
positive by CISH were HPV 6 and 11 positive in 23 
(45.1%) cases, HPV 16 and 18 positive in 6 (11.8%) 
cases, and HPV 31 and 33 positive in 11 (21.6%) 
cases. A combination of HPV 6 and 11, and 16 
and 18 was seen in 2 (3.9%); and a combination of 
HPV 6 and 11, and 31 and 33 was seen in 7 (13.7%) 
cases. The distribution by nationality of HPV types 
in breast carcinoma cases determined positive for 
HPV-CISH is shown in Table 1.
In the Kuwaiti population, HPV 6 and 11 were 
present alone in 11 of 27 (40.7%) cases. In 9 cases, 
HPV 6 and 11 were found in combination with 
HPV 16 and 18 (2 cases, 7.4%) and HPV 31 and 
33 (6 cases, 22.3%). All three types were detected 
in one Kuwaiti woman. High risk HPV 16 and 18 
were detected in 2 (7.4%) Kuwaiti women while 
the intermediate-risk HPV 31 and 33 alone were 
detected in 5 (18.5%) Kuwaiti women [Table 1].
The distribution of HPV types and the age 
groups of the cases with breast carcinoma are 
shown in Table 2. The low-risk HPV types 6 and 11 
were seen in all decades of life. The prevalence was 
higher in patients greater than 30 years of age. The 
high-risk HPV types 16 and 18, and intermediate-
risk HPV 31 and 33 were detected in the fifth, sixth 
and seventh decades of life.
The correlation of HPV types determined by 
CISH according to age, histological grade, tumour 
size, lymph node metastases, ER, PR and HER2/
neu status is shown in Table 3. Univariate analysis 
between the HPV status determined by CISH was 
done with the histological grade of the tumour, size 
of the tumour, lymph node metastases, ER, PR and 
HER2/neu. No statistically significant differences 
were observed. Linear-by-linear association did not 
show significant correlation with the prognostic 
parameters although a trend was observed in 
that HPV types 16 and 18 were associated with 
lymphnodal metastases; however, the numbers 
were too limited to come to a definitive conclusion.
Discussion
This study documented HPV and the various types 
(6, 11, 16, 18, 31 and 33) in Kuwaiti and non-Kuwaiti 
women. We found HPV determined by CISH in 51 
(35.41%) cases of invasive ductal carcinoma of the 
breast. 
The reported prevalence of HPV in breast 
tissue between 1992 and 2012 varies between 4% 
in Mexico to 86% in the USA.26 HPV prevalence 
as determined by the PCR method was seen in 
61.1% cases in Syria.23 Simoes et al. conducted 
a comprehensive systematic review of studies 
Table 1: Distribution by nationality of human papilloma 
virus (HPV) types in breast cancer cases testing positive 
for HPV by chromogenic in-situ hybridisation
HPV 
types






































































HPV = human papilloma virus; CISH = chromogenic in situ 
hybridisation; N/A = not applicable; [  ] = percentage within HPV 
types.
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addressing worldwide HPV prevalence rates.27 In 
this meta-analysis of 29 studies comprising of 2,211 
samples, the overall prevalence of HPV in breast 
carcinoma was 23% with great variation worldwide, 
ranging from 13.4–42.8%.27 This large worldwide 
variability could be related to methodology. Most 
studies utilise the PCR technique, which is more 
sensitive but less specific as compared to in-situ 
hybridisation techniques, which show the virus 
location.24
The HPV types found in our study, as 
determined by CISH, were HPV 6 and 11 (45.1%); 
HPV 16 and 18 (11.8%); and HPV 31 and 33 
(21.6%). More than one HPV type was seen in 11 
cases (21.6%). A combination of HPV 6 and 11 and 
HPV 16 and 18 was seen in two cases (3.9%) while 
a combination of HPV 6 and 11 and HPV 31 and 
33 was seen in 7 cases (13.7%). In two cases (3.9%), 
all HPV types examined were identified [Table 1]. 
In the Kuwaiti population, the distribution of HPV 
types 6 and 11; 16 and 18, and 31 and 33 were 
40.7%, 7.4% and 18.5%, respectively, while in non-
Kuwaitis it was 42.1%, 21.1% and 26.2%, respectively 
[Table 1]. A combination of HPV 6 and 11, and 
16 and 18 was seen in 7.4% of the Kuwaiti women 
while a combination of HPV 6 and 11, and 31 and 
33 was found in 22.3%. All three HPV types were 
seen in one woman. In the non-Kuwaitis, only one 
(5.3%) case had a combination of HPV 6, 11, 31, 33 
[Table 1]. The high- and intermediate-risk HPV 
types were found in 16 of the 27 (59.3%) Kuwaiti 
women and 11 of the 19 (47.9%) non-Kuwaitis 
Table 3: Distribution of human papilloma virus types in breast cancer cases with prognostic parameters (n = 51)















‡ER (IHC)  
n = 50 
§PR (IHC)  
n = 48 
¶HER2/neu 
(IHC)  
n = 49 
6, 11, n (%) 23 (45.1) 4/16/3 0/7/16 12 (52.2) 17 (73.9) 15 (65.2) 4 (17.4)
16, 18, n (%) 6 (11.8) 0/4/2 1/3/2 6 (100) 4 (80) 2 (66.7 0 (0)
31, 33, n (%) 11 (21.6) 1/8/2 0/6/5 7 (77.8) 10 (90.9) 10 (90.9) 2 (8.7)
6, 11 & 16, 
18, n (%)
2 (3.9) 0/1/1 0/0/2 2 (100) 0 (0) 0 (0) 1 (50) 
6, 11 & 31, 
33, n (%)
7 (13.7) 1/4/1 0/3/4 3 (50) 4 (57.1) 3 (42.9) 1 (14.3)
6, 11 16, 
18 & 
31, 33, n (%)
2 (3.9) 0/2/0 0/0/2 2 (100) 1 (50) 1 (50) 0 (0)
Total 51 6/35/9 1/19/31 32(62.7) 36 (72) 31 (64.6) 8 (16.3)
*P = 0.895, ** P = 0.225, †P = 0.134, ‡P = 0.129, §P = 0.125, ¶P = 0.400.
HPV = human papilloma virus; ER = oestrogen receptors; IHC = immunohistochemistry; pos = positive; neg = negative; PR = progesterone receptors; 
HER2/neu = human epidermal growth factor receptor 2.
Table 2: Distribution of age according to human papilloma virus (HPV) types in breast cancer cases (n = 51)






6 & 11 16 & 18 31 & 33 6 & 11 + 
16 & 18 
6 & 11 + 
31 & 33 
6 & 11 + 
16 & 18 + 
31 & 33
n (% within HPV types); n [% within age groups]
21–30 2 [3.9] 2 [8.7] - - - - -
31–40 8 [15.7] 3 [13] 1 [16.7] 3 [27.3] - - 1 [50]
41–50 8 [15.7] 4 [17.4] - 1 [9.1] 1 [50] 2 [28.6] -
51–60 15 [29.4] 8 [34.8] 2 [33.3] 2 [18.2] 1 [50] 1 [14.3] 1 [50]
61–70 12 [23.5] 4 [17.4] 2 [33.3] 3 [27.3] - 3 [42.8]
≥71 6 [11.8] 2 [8.7] 1 [16.7] 2 [18.2] - 1 [14.3] -
Total 51 23 (45.2) 6 (11.7) 11 (21.6) 2 (3.9) 7 (13.7) 2 (3.9)
Issam M. Francis, Bushra Al-Ayadhy, Shafiqa Al-Awadhi, Kusum Kapila and Fahd Al-Mulla
Clinical and Basic Research | 532
[Table 1]. This is the first time that the association 
of HPV types with breast carcinoma has been 
documented in Kuwaitis and non-Kuwaitis 
in Kuwait. We have no explanation for these 
differences, and more research work needs to be 
undertaken.  
Di Lonardo et al. were the first to report HPV 
16 DNA using PCR in 29.4% of 40 breast cancer 
specimens.14 Using PCR, HPV types 11, 16 and 
18 have been reported with increasing frequency 
from women living in USA and Brazil, while HPV 
type 18 was present in the majority of Australian 
women.12,16,17 HPV 33 was seen in 34.1% of breast 
carcinoma cases in Japan.28 Studies from the Middle 
East reveal that HPV types 18, 33 and 35 were 
present in cancerous and normal breast tissue in 
Turkish women.20 In Syria, a prevalence of HPV 
16 (9%), HPV 33 (56%) and HPV 35 (37%) was 
observed.23 In 24 (34.78%) women, more than one 
HPV type was detected.23 Only two studies have 
been reported where in-situ PCR (IS-PCR), which 
involves amplification to detect HPV in breast 
tissue, was used.13,24
Very few studies have tried to correlate the 
presence of HPV in breast carcinoma cases with 
other prognostic markers.12,29,30 In our study, 51 HPV 
DNA-positive cases, as determined by CISH, were 
correlated with the age of the patients, histological 
grades, tumour sizes, lymph nodal metastases, ER, 
PR and HER2/neu expression. We did not find any 
significant correlation as our numbers were limited; 
thus, more work needs to be done in this regard. 
Kan et al. using PCR for detecting HPV, did not 
find any significant correlation between grade of 
tumour, mortality of patients, ER, PR, ERB-B2, p53 
expression and the presence of p53 mutations.12 
Cantu de Leon, using PCR for HPV determination, 
found that the greater the tumour size the greater 
the probability of finding viral DNA in the tumour, 
but not in tumours larger than 4 cm where the viral 
DNA appeared to be lost.29 However, there was no 
correlation with the histological grade, ER, PR or 
clinical stage.29 Mou et al., in a retrospective study 
from China of 62 breast cancer patients tested 
for HPV status by nested PCR, did not find any 
significant correlation between the presence of 
HPV and patient age, tumour size, metastases, or 
ER and PR status.30 
There are several limitations to this study apart 
from the limited sample size. While the nucleic acid 
is degraded in archival paraffin-embedded tissue, 
CISH should still be considered a relevant technique 
when used on such material. Although IHC is 
not as sensitive a technique as PCR, we did not 
perform PCR in this study as in-situ methods have 
the advantage of detecting HPV in individual cells, 
which can be categorised as benign or malignant 
under conventional light microscopy. 
Conclusion
The frequency of HPV in breast carcinoma cases in 
Kuwait was 35.4% when determined by the CISH 
method. The CISH method was useful in detecting 
HPV in malignant cells and should be considered 
as part of a standard investigation. Of the 51 HPV-
positive cases, 27 (52.9%) were Kuwaitis. Both 
low-risk and high-risk HPV types, along with a 
combination of HPV types, were detected in the 
Kuwaiti population. No correlation was observed 
with the prognostic parameters.
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